Racial Differences in CYP3A4 Genotype and Survival Among Men Treated on Radiation Therapy Oncology Group (RTOG) 9202: A Phase III Randomized Trial
- Departments of Radiation Oncology, University of California San Francisco, San Francisco, CA (United States)
- RTOG Statistical Headquarters, Philadelphia, PA (United States)
- University of Pennsylvania, Philadelphia, PA (United States)
- Wayne State University, Detroit, MI (United States)
- SUNY Downstate Medical Center, Brooklyn, NY (United States)
- Radiology Associates of Sacramento, Sacramento, CA (United States)
- University of Western Ontario, London, Ontario (Canada)
- Fox Chase Cancer Center, Philadelphia, PA (United States)
- Massachusetts General Hospital, Boston, MA (United States)
- University of Michigan, Ann Arbor, MI. (United States)
Purpose: Inherited genotypes may explain the inferior outcomes of African American (AA) men with prostate cancer. To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4*1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02. Methods and Materials: From 1,514 cases, we evaluated 56 (28.4%) of 197 AA and 54 (4.3%) of 1,274 European American (EA) patients. All patients received goserelin and flutamide for 2 months before and during RT (STAD-RT) {+-} 24 months of goserelin (long-term androgen deprivation plus radiation [LTAD-RT]). Events studied included overall survival and biochemical progression using American Society for Therapeutic Radiology and Oncology consensus guidelines. Results: There were no differences in outcome in patients in with or without CYP3A4 data. There was an association between race and CYP3A4 polymorphisms with 75% of EAs having the Wild Type compared to only 25% of AA men (p <0.0001). There was no association between CYP3A4 classification or race and survival or progression. Conclusions: The samples analyzed support previously reported observations about the distribution of CYP3A4*1B genotype by race, but race was not associated with poorer outcome. However, patient numbers were limited, and selection bias cannot be completely ruled out.
- OSTI ID:
- 21036201
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 69, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2007.03.008; PII: S0360-3016(07)00459-2; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Recognizing False Biochemical Failure Calls After Radiation With or Without Neo-Adjuvant Androgen Deprivation for Prostate Cancer
Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation